This recent confirmation provides further validation of RIPA mixing studies as a workable solution for identification/discrimination of 2B/PT VWD, especially given that the latest 2021 American Society of Hematology, International Society on Thrombosis and Haemostasis, National Hemophilia Foundation, and World Federation of Hemophilia guidelines on VWD diagnosis seem to favor genetic testing, which is not always available to laboratories or which may be cost prohibitive for laboratories in developing/resource-poor countries. This evidence concerns the gene VWF and hemophilia.